Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGNDZ) Receivables - Other (2017 - 2018)

Ligand Pharmaceuticals (LGNDZ) has disclosed Receivables - Other for 2 consecutive years, with $8.0 million as the latest value for Q4 2018.

  • Quarterly Receivables - Other changed N/A to $8.0 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2018, changed N/A year-over-year, with the annual reading at $8.0 million for FY2018, N/A changed from the prior year.
  • Receivables - Other hit $8.0 million in Q4 2018 for Ligand Pharmaceuticals, up from $5.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $8.0 million in Q4 2018 to a low of $5.0 million in Q2 2017.